KIR2DL1/CD158a 293T Cell Transient Overexpression Lysate

Product Discontinued

KIR2DL1/CD158a 293T Cell Transient Overexpression Lysate Summary

• Description: Quality control test: Transient overexpression cell lysate was tested with Anti-KIR2DL1 antibody by Western Blots. Plasmid: pCMV-KIR2DL1 full-length
• Specificity: KIR2DL1/CD158a 293T Cell Transient Overexpression Lysate(Denatured)
• Gene: KIR2DL1

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Store at -80C. Avoid freeze-thaw cycles.
• Buffer: 1X Sample Buffer (50 mM Tris-HCl, 2% SDS, 10% glycerol, 300 mM 2-mercaptoethanol, 0.01% Bromophenol blue)

Lysate Details for Array

• Type: 293T Cell Transient Overexpression
• Protein State: Denatured

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for KIR2DL1/CD158a 293T Cell Transient Overexpression Lysate

• CD158 antigen-like family member A
• CD158a antigen
• CD158a
• CD158Ankat1
• cl-42
• killer cell immunoglobulin-like receptor 2DL1
• killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1
• killer Ig receptor
• killer inhibitory receptor 2-2-1
• KIR221
• KIR2DL1
• MHC class I NK cell receptor
• Natural killer-associated transcript 1
• NKAT
• NKAT-1
• NKAT1KIR-K64
• p58 killer cell inhibitory receptor KIR-K64
• p58 natural killer cell receptor clones CL-42/47.11
• p58 NK cell inhibitory receptor NKR-K6,47.11
• p58 NK receptor CL-42/47.11
• p58.1 MHC class-I-specific NK receptor
• p58.1

Background

KIRDL2, also known as CD158a, belongs to the killer-cell immunoglobulin-like receptor (KIR) gene family expressed by natural killer (NK) cells and functions in inhibitory signaling (1,2). The KIR genes consisting of 15 gene loci and two pseudogenes are located on chromosome 19 and segregated into halptype A or B depending on gene composition (1). Human KIR2DL1 belongs to haplotype A and is synthesized as a protein of 348 amino acids (aa) in length with a theoretical molecular weight (MW) of 38.5 kDa (3). The KIR2DL1 protein consists of two extracellular immunoglobulin (Ig)-like C2 domains, a transmembrane domain, and a long cytoplasmic tail containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) (1,3). KIR2DL1 binds human leukocyte antigen (HLA) alleles with the C2 supratype, resulting in an inhibitory immune response and suppression of NK cell activity to target cells (1,2). KIR2DL1 has been shown to be a potential clinical biomarker for diseases related to suppressed NK cell function (4). An increase in inhibitory receptors such as KIR2DL1/CD158a is observed in certain pathologies like endometriosis and multiple myeloma (4,5). Therapeutic inhibition of KIR2DL1 may be a potential treatment option for endometriosis patients (5). Additionally, blocking of KIR2DL1 combined with rituximab, and anti-CD20 monoclonal antibody, has shown increased NK cell cytotoxicity than just the antibody itself (5).

References

1. Debska-Zielkowska J, Moszkowska G, Zielinski M, et al. KIR Receptors as Key Regulators of NK Cells Activity in Health and Disease. Cells. 2021;10(7):1777. Published 2021 Jul 14. https://doi.org/10.3390/cells10071777

2. Goodson-Gregg FJ, Krepel SA, Anderson SK. Tuning of human NK cells by endogenous HLA-C expression. Immunogenetics. 2020;72(4):205-215. https://doi.org/10.1007/s00251-020-01161-x

3. Uniprotkb (P43626)

4. Konjevic G, Jurisic V, Jovic V, et al. Investigation of NK cell function and their modulation in different malignancies. Immunol Res. 2012;52(1-2):139-156. https://doi.org/10.1007/s12026-012-8285-7

5. Hoogstad-van Evert J, Paap R, Nap A, van der Molen R. The Promises of Natural Killer Cell Therapy in Endometriosis. Int J Mol Sci. 2022;23(10):5539. Published 2022 May 16. https://doi.org/10.3390/ijms23105539

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Lysates are guaranteed for 6 months from date of receipt.

Bioinformatics

• Gene Symbol: KIR2DL1